Articles tagged with Parkinsons Disease
A new biological classification system for Parkinson's disease, known as SynNeurGe (S-N-G system), has been introduced. This classification considers three key components: pathological α-synuclein in tissues or cerebrospinal fluid, neuroimaging techniques, and pathogenic gene variants. The S-N-G system offers a detailed framework for u...
A nonrandomized controlled trial found that deep brain stimulation in advanced Parkinson disease improved mobility and maintained quality of life at 5-year follow-up. In contrast, standard-of-care medication worsened quality of life mainly due to its unfavorable effect on mobility.
Researchers developed a wireless method to effectively reduce motor dysfunction in people with Parkinson's disease using magnetogenetics. The treatment showed improved motor function and no significant damage in and around the brain, suggesting it could be a safer alternative to traditional implanted DBS systems.
Researchers at Duke University developed an adaptive deep brain stimulation therapy for Parkinson's disease, targeting two key brain structures and using a novel self-adjusting device. The study found that this approach improved motor symptoms and reduced medication doses in six patients.
The CACHE Challenge series has identified seven promising molecules with potential for new, more effective drugs for familial Parkinson's disease. The open science competition, funded by The Michael J. Fox Foundation and Conscience, used AI to predict hits and validated experimental results.
Researchers from Aarhus University discovered a newly found receptor called CD163 that appears to protect against Parkinson's disease in females. The protein is involved in the immune response and seems to exert a neuroprotective role particularly relevant in females.
Researchers discovered a previously unreported neuron type with vulnerability in Parkinson's disease, shedding light on the complexity of the disease and potential therapeutic targets. The study identified distinct transcriptomic signatures of this neuron type and found reduced RIT2 expression in Parkinson's disease patients.
A potential Parkinson's medicine, Syn-RiboTAC, targets RNA to slow or stop disease progression by preventing the buildup of toxic protein alpha-synuclein. In early studies, reducing alpha-synuclein levels by even 25% or more is therapeutically beneficial, with the compound showing good selectivity and improved brain-barrier penetration.
Researchers developed a novel test that detects single ⍺-synuclein fibrils in patient samples to identify patients with Parkinson's disease earlier. This breakthrough has the potential to create early applicable molecular diagnostics, improve clinical trials, and facilitate drug screening for neurodegenerative diseases.
Researchers at Boston University's Center for Neurorehabilitation have made two important advances that may help people with Parkinson's disease walk more smoothly. Wearable soft robotic apparel and a music-based technology were tested in studies, showing promising results in increasing walking duration and distance.
A soft, wearable robot was used to help a person living with Parkinson’s disease walk without freezing, eliminating the debilitating symptom and allowing them to regain their independence. The device provided instantaneous effects and consistently improved walking in a range of conditions.
A newly identified genetic mutation in a small protein provides significant protection against Parkinson's disease. The variant, SHLP2, is found primarily in people of European descent and reduces the risk of Parkinson's by twofold.
Scientists at St. Jude Children's Research Hospital have determined the complex structure of Parkinson’s disease-related proteins LRRK2 and Rab29, revealing how they work synergistically to cause the disease. The structures provide an atomic-scale map to trace how different mutations affect function within this complex, with implicatio...
Researchers have discovered a protein called NEMO that prevents the formation of toxic protein aggregates in Parkinson's disease. By labeling proteins for degradation and interacting with autophagy machinery, NEMO promotes the breakdown of harmful aggregates, potentially leading to new therapeutic strategies.
Researchers identified key proteins involved in the process, including mTOR and TSC2, which can be targeted to slow or halt disease progression. The study's findings suggest new therapeutic strategies to save dopaminergic neurons and alleviate motor and cognitive symptoms.
A world-first brain stimulation treatment is being developed to treat symptoms of Parkinson's disease and epilepsy using ultrasound technology. The endovascular focused ultrasound technique could significantly improve the quality of life for thousands of people living with neurological diseases.
Scientists have successfully grown neurons from stem cells that can repair damaged brain tissue after stroke, offering new hope for treatments. The technology also holds promise for studying neurodegenerative diseases like Alzheimer's, Parkinson's, and spinal cord injury.
A study published in Molecular Cell describes how bacteria build a form of ubiquitin that helps cells communicate. The research sheds light on how different enzymes impact this protein during infection, providing an important first step towards understanding its role in diseases like Parkinson's and breast cancer.
A review article links pesticide exposure to an increased risk of developing Parkinson's disease through alterations in the gut microbiota. The authors recommend reducing or replacing agrochemicals and implementing coordinated efforts to develop standardized biomarkers for gut integrity and microbiome changes.
A study found increased brain inflammation and structural changes in special operations personnel exposed to blasts, potentially increasing the risk of long-term brain-related disease. The research suggests that repetitive exposure to low-level blasts may cause brain injuries and highlights the need for better protective measures.
A new organoid model replicates the dopaminergic system's structure, connectivity, and functionality, shedding light on its intricate functionality and potential implications for Parkinson’s disease. The model also uncovers the enduring effects of chronic cocaine exposure on the dopaminergic circuit, even after withdrawal.
A new publication in Nature Communications has developed a method to produce high-purity dopamine cells from human stem cells, offering a potential therapeutic approach for treating Parkinson's disease. The research aims to reduce recovery time and minimize the risk of relapse and medication use.
UTEP researchers develop a therapy based on caffeic-acid derived from spent coffee grounds to protect brain cells from damage. The treatment has potential to prevent neurodegenerative disorders such as Alzheimer's and Parkinson's by removing free radicals and inhibiting amyloid protein aggregation.
A novel study suggests that nanoparticles of polystyrene plastic can interact with the protein alpha-synuclein in the brain, promoting conditions for Parkinson's disease. This finding raises concerns about the impact of environmental factors on human biology and highlights the need for further research.
Researchers at the University of Wisconsin-Madison have successfully generated human norepinephrine neurons from stem cells using a key protein called ACTIVIN-A. These LC-NE neurons may serve as models for disease in humans, enabling scientists to screen drugs and answer questions about neurodegeneration.
A new study has uncovered the molecular causes of a rare developmental brain condition in children, known as Autosomal Recessive ACBD6-related disorder. The research team identified defects in the acyl-CoA-binding domain-containing protein 6 (ACBD6) gene as the underlying cause, leading to delays in cognitive and motor skills development.
Researchers at Beth Israel Deaconess Medical Center have made a groundbreaking discovery that inhibiting a specific enzyme can halt the progression of Parkinson's disease in a mouse model. The findings suggest that reducing USP30 may slow or prevent PD progression, paving the way for novel therapeutics.
Researchers at UMass Lowell found that anti-inflammatory bacteria were less abundant in people with Parkinson's disease, suggesting a potential biomarker for early diagnosis. A new study on Latinos may also uncover novel biomarkers for Alzheimer's disease.
A UTHealth Houston researcher is leading a large-scale implementation trial to address disparities in palliative care for Parkinson's disease and related dementia patients. The study aims to reduce low-value and unequal care, improve end-of-life care, and promote health equity.
Researchers developed a handheld, wireless biosensor to detect Alzheimer's and Parkinson's biomarkers from saliva and urine samples. The device has shown high accuracy comparable to existing state-of-the-art methods.
The C-Path Neuroscience Annual Workshop brought together stakeholders to chart a transformative course for neurology research and drug development, focusing on chronic progressive diseases such as Alzheimer's and Parkinson's. Key highlights included recommendations for innovative therapies and tools to address complex disorders.
Researchers have identified a crucial biological trigger of Huntington's disease, finding that methylation converts an important protein into waste. By targeting this process, they may develop effective therapies for other neurodegenerative diseases.
Researchers at Texas A&M University have found a correlation between flavonoid compounds and reduced endometriosis symptoms. Flavonoids like Quercetin and Kaempferol show promise in easing inflammation, with studies suggesting they may help suppress the symptoms of inflammatory diseases like endometriosis.
Researchers used PET scans to detect low cardiac norepinephrine levels in individuals with Parkinson's risk factors, finding that those with low radioactivity were highly likely to develop Parkinson's or Lewy body dementia. The study suggests a potential biomarker for early detection and treatment of these diseases.
Researchers found that changing treatment can lead to significant improvement in mobility and quality of life for patients with advanced Parkinson's disease. A nationwide registry is planned to develop scientifically sound guidelines for combination therapies.
A novel gene therapy strategy has been developed to specifically target and activate the direct pathway in Parkinson's disease-affected neurons, leading to improved motor symptoms such as bradykinesia and tremor. The approach has shown faster onset and longer duration compared to traditional L-Dopa treatment.
A research team discovered that alpha-synuclein activates the plasma membrane calcium pump in negatively charged environments, preventing toxic cell buildup. This understanding has profound implications for unraveling early Parkinson's disease processes and potential diagnostic and therapeutic strategies.
Researchers investigate centro-cingulate network changes and cholinergic innervation deficits in Parkinson disease and normal aging. Studies reveal significant correlations between centro-cingulate changes and cognitive impairments, motor symptoms, and age.
A recent study found that people living in areas with high levels of fine particulate matter have a 56% greater risk of developing Parkinson's disease. The Mississippi-Ohio River Valley and parts of Texas, Kansas, and eastern Michigan were identified as regions with higher rates of the disease.
Researchers describe traveling waves of acetylcholine in the striatum, revealing a new kind of neurochemical wave. The study proposes a mathematical mechanism by which simultaneous waves of acetylcholine and dopamine arise, maintaining balance in the brain's striatum.
Research suggests that Tai Chi practice can slow Parkinson's disease progression, improve non-motor symptoms, and lower medication needs over time. The study found significant benefits in disease severity, cognitive function, sleep quality, and complication prevalence in the Tai Chi group compared to the standard care group.
A team of researchers has created a 'proteomic clock' that can predict a healthy person's age based on their protein profile, revealing accelerated aging due to diseases. The study also detected proteins associated with Parkinson's disease in eye fluid, offering a potential pathway for earlier diagnoses.
Researchers at The Florey and Austin Health have discovered a way to detect Parkinson's disease 20-30 years before symptoms appear using a known biomarker called F-AV-133. PET scans show significant neuronal loss in three key brain regions, suggesting the biomarker is more sensitive than current methods.
A recent study by the University of Vienna and collaborators suggests that microbial metabolites may play a role in inducing Parkinson's-like symptoms. The researchers identified a specific bacterial metabolite that selectively damages dopamine-producing neurons, mirroring the neuronal loss observed in Parkinson's disease.
A study by researchers at the University of California - Riverside found that certain aspects of video game play can stimulate dopamine release and potentially aid in treating Parkinson's disease symptoms. The research suggests a promising new approach for managing the condition.
A new study by the National Neuroscience Institute suggests that drinking coffee and tea containing caffeine can significantly reduce the risk of Parkinson's disease in Asians who carry specific genetic variants. The study found that those who consumed higher amounts of caffeine had lower risks, even at moderate doses.
A significant breakthrough sheds light on Parkinson's disease mechanisms, revealing that mitochondrial DNA damage triggers the spread of debilitating symptoms. The researchers' findings offer promising potential for innovative treatments and diagnostics.
A large study of 491,000 participants found that loneliness was associated with an increased risk of developing Parkinson's disease. The findings suggest that loneliness is a significant psychosocial determinant of health and may contribute to the development of the neurodegenerative disorder.
A UNIGE team investigated the destruction of neurons at different times of the day using fruit fly models and found that cellular stress was more deleterious to neurons at night. This suggests that the circadian clock exerts a protective effect on dopaminergic neurons against oxidative stress.
In Parkinson's disease, the cerebral cortex compensates for lost dopamine cells by taking over tasks, which determines symptom severity. Exercise can stimulate this compensation and slow down disease progression.
A new study explores how alpha-synuclein disrupts metabolic processes in neurons. Researchers used NanoSIMS imaging techniques to visualize isotopic variations and found changes in carbon turnover, suggesting increased metabolic demands on affected cells.
Researchers have discovered a peptide that stabilizes the normal structure of alpha-synuclein protein, preventing misfolding and toxic clumps. This breakthrough could lead to new therapeutic developments for neurodegenerative diseases like Parkinson's.
Researchers identified potential therapeutic targets for Alzheimer's disease and other conditions using a new approach combining AI-driven target identification with protein phase separation analysis. The study provides insights into the role of protein phase separation in human disease and its potential as a therapeutic target.
Researchers at Aarhus University have unraveled the mystery of how lipid layers on cell surfaces accelerate Parkinson's disease misfolding. The study reveals that elevated concentrations cause alpha-synuclein to adopt an upright conformation, leading to easier refolding into dangerous aggregates.
A recent Cleveland Clinic trial found that augmented reality therapy, such as the Dual-task augmented Reality Treatment (DART), can improve posture and stability in individuals with Parkinson's disease. The digital platform uses a headset to guide exercises and track progress, allowing for more widespread use of physical therapy.
Researchers at Lund University discovered a blood biomarker called DOPA decarboxylase (DCC) that can identify Parkinsonian diseases by measuring elevated levels in the blood, regardless of disease progression
A new Northwestern Medicine study reveals that a dysfunction in the neuron's synapses leads to deficits in dopamine and precedes neurodegeneration in Parkinson's disease. The findings suggest targeting dysfunctional synapses before neurons degenerate may represent a better therapeutic strategy.
Prof. Dr. Thomas Gasser has been awarded the Breakthrough Prize in Life Sciences for discovering genetic risk factors for Parkinson's disease. He hopes his findings will lead to treatments targeting molecular causes and prevent or delay the onset of the disease.
Researchers developed a new imaging technique using Bessel beam two-photon microscopy to detect stalling in brain capillaries, which can indicate acute neurological issues. The approach generates clear images of all capillaries every two seconds, providing better temporal resolution and enabling the detection of short stalling events.
Doctors treating Parkinson's patients need to focus on the emotional and social impacts of stigma, in addition to motor symptoms. Stigma can lead to feelings of loneliness, depression, anxiety, and isolation, which significantly affect quality of life.